Aug. 19 at 12:55 AM
$ALGS What I like about this investment mid to long:
-Robust potential best in class pipeline
-Relatively low (~5M) number of shares
-Partnership with Amoytop
-While Aligos’ current cash position only supports them through EOY 2026, and we don’t have details on the exact Amoytop milestone structure, I think Aligos leadership believes the milestone requirements are achievable and the subsequent payouts will fund them through development and commercialization of ALG-000184 and ALG-170675 in the US. If Aligos can avoid stock dilution and keep public float at ~5M shares, I think the current estimated average of
$56 per share is reasonable if not low.
-Larry Blatt CEO has previous experience successfully cofounding and leading Alios BioPharma until it was purchased by Janssen Pharmaceutical Companies of Johnson & Johnson in 2014 for
$1.75 billion.
